Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 4, 2005, Pages 575-581

  Schotte, H ^a   Schluter B ^a   Drynda, S ^b   Willeke, P ^a   Tidow, N ^a   Assmann, G ^a   Domschke, W ^a   Kekow, J ^b   Gaubitz, M ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA; ETANERCEPT; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; LONG TERM CARE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-10; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROMOTER REGIONS (GENETICS); RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 16344376392     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.027672     Document Type: Article

References (43)

1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
2. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
3. den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AM, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002;61:311-18.
4. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149-55.
5. Weyand CM, Klimiuk PA, Goronzy JJ. Heterogeneity of rheumatoid arthritis: from phenotypes to genotypes. Springer Semin Immunopathol 1998;20:5-22.
6. Miterski B, Drynda S, Boschow G, Klein W, Oppermann J, Kekow J, et al. Complex genetic predisposition in adult and juvenile rheumatoid arthritis. BMC Genet 2004;5:2.
7. Klimiuk PA, Goronzy JJ, Bjornsson J, Beckenbaugh RD, Weyand CM. Tissue cytokine patterns distinguish variants of rheumatoid synovitis. Am J Pathol 1997;151:1311-19.
8. Wanidworanun C, Strober W. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 1993;151:6853-61.
9. Moore KW, de Wool MR, Coffman RL, O'Gorra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
10. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995;154:5492-9.
11. Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, Davis LS, et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:96-104.
12. Perez L, Orte J, Brieva JA. Terminal differentiation of spontaneous rheumatoid factor-secreting B cells from rheumatoid arthritis patients depends on endogenous interleukin-10. Arthritis Rheum 1995;38:1771-6.
13. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Levarht EW, Breedveld FC, Verweij CL. Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients. Arthritis Rheum 1998;41:2211-20.
14. Reparon-Schuijt CC, van Esch WJ, van Kooten C, Schellekens GA, de Jong BA, van Venrooij WJ, et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum 2001;44:41-7.
15. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-3.
16. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5′ flanking sequence. Immunogenetics 1997;46:120-8.
17. Eskdole J, Keijsers V, Huizinga T, Gallagher G. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999;1:151-5.
18. Eskdale J, Gallagher G. A polymorphic dinucleotide repeat in the human IL-10 promoter. Immunogenetics 1995;42:444-5.
19. Eskdale J, Kube D, Gallagher G. A second polymorphic dinucleotide repeat in the 5′ flanking region of the human IL10 gene. Immunogenetics 1996;45:82-3.
20. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 1998;95:9465-70.
21. Eskdale J, McNicholl J, Wordsworth P, Jonas B, Huizinga T, Field M, et al. Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet 1998;352:1282-3.
22. Padyukov L, Lampa J, Heimburger M, Ernestam S, Cederholm T, Lundkvist I, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9.
23. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position-308 or the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48:1849-52.
24. Martinez A, Salido M, Bonilla G, Pascual-Salcedo D, Fernandez-Arquero M, de Miguel S et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004;50:1077-82.
25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
26. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster Study. Am J Cardiol 1992;70:733-7.
27. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;3B:44-8.
28. van Gestel AM, Prevoo ML, 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
29. Higuchi R. Simple and rapid preparation of samples for PCR. In: Ehrlich HA, eds. PCR-Technology, principles and applications for DNA amplification. New York: Stockton Press, 1989:31-8.
30. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
31. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.
32. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995;59:97-105.
33. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-6.
34. Phillips K, Husni ME, Karlson EW, Coblyn JS. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002;47:17-21.
35. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003;42:617-21.
36. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelinatian occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
37. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977-83.
38. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.
39. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis foctor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.
40. MacKay K, Milicic A, Lee D, Tikly M, Laval S, Shatford J, et al. Rheumatoid arthritis susceptibility and interleukin 10: a study of two ethnicolly diverse populations. Rheumatology (Oxford) 2003;42:149-53.
41. Lard LR, van Gaalen FA, Schonkeren JJ, Pieterman EJ, Stoeken G, Vos K, et al. Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 2003;48:1841-8.
42. Lassere MND, Farmer K, Portek I, Bird P, Edmonds J, Shnier R, et al. Synovial cytokine mRNA predicts joint damage in RA: a 2 year prospective study [abstract]. Arthritis Rheum 2002;46(suppl 9):S371.
43. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, et al. Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis. Ann Rheum Dis 2003;62:472-5.